Alan Barge Email & Phone Number

London, England, Gb

Cambridge, Cambridgeshire, Gb

This is the principle leadership role in Oncology and Infection, directly responsible for the overall company strategy in oncology and infection, from drug discovery to proof-of-concept. Chairman of the Therapy Area Portfolio Team and accountable for the design and delivery of all projects and budgetary accountability of approximately $200M per annum, and managing a portfolio of approximately 20 projects in pre-clinical and early clinical development. Direct responsibility for leadership groups in UK, US and Asia Key achievements:Implementation of strategic external alliance network for translational science and early phase development in Europe, US and AsiaLead evaluation and acquisition of Kudos Pharmaceuticals in Cambridge, yielding new DNA repair expertise and clinically leading PARP-inhibitor olaparibInitiated and signed key strategic alliance with Merck in development of targeted agent combinationsBuilt World-leading Personalised-Medicine group in oncologyInitiated and lead significant change program using external expertise and insights from business academics and other industries

Cambridge, Cambridgeshire, Gb

Cambridge, Cambridgeshire, Gb

This position, reporting to Exec. VP Clinical Development, is responsible for the design, execution delivery, interpretation and presentation of all translational and clinical data for all phases of development globally. It involved the identification, recruitment, mentoring and development of a group of 95 scientists, clinicians and clinical operations staff, in Europe, the US and Asia. The role incorporated the direction and leadership of key interactions with regulatory agencies, health-technology assessment (HTA) agencies and academics globally, and was a member of the Therapy Area Portfolio Team, and Clinical Development Leadership Team.Key achievementsRecruitment, mentoring and development of group of 95 clinicians, scientists and operational staff in UK, US and AsiaEstablishment of Personalised Medicine group in AZ OncologyIdentification of 12 key strategic alliance centres for early phase oncology development in US, EU and AsiaEstablishment of key strategic alliances with NCI, CRUK and Korean Cancer Study Group (KCSG)Leadership of key regulatory presentations at FDA-ODAC, CHMP and MHLW

Cambridge, Cambridgeshire, Gb

Cambridge, Cambridgeshire, Gb

Cambridge, Cambridgeshire, Gb

This newly-established position was responsible for all new oncology projects from mid-stage pre-clinical to end of Phase II, for the late-stage pre-clinical and translational evaluation, up until proof-of-concept (PoC). It required the building of a large cross-functional team internally, and key alliances with major early-phase sites externally, in the EU, US and Asia.Key achievements:Established translational science and biomarker capabilities at AZSet up key external alliances with Phase I units in US, EU and AsiaTook 6 compounds into Man and completed Phase IIDeveloped relationships with MHLW (Japan) and SFDA (China) for early phase evaluation

This position was established on a strategic Key Brand Team and was responsible for all global clinical and scientific development of gefitinib (Iressa) following its initial failure in Phase III. The goal was to completely re-evaluate and re-design the development program, and achieve approval globally.Key achievements: Re-evaluated and re-designed development program to target specific patient subset (EGFR Mutation +)Lead development and execution of targeted development program, biomarker validation, and development of diagnostic technologiesExecuted clinical programs worldwide leading to EU approval and revision of approvals in Asia (and ongoing FDA submission)Lead presentations at FDA ODAC, CHMP (2), MHLW (4) Health Canada and TGALead interactions with Health Technology Assessment Agencies worldwide

This position was the third role recruited by Amgen in Europe in 1990, and was responsible for initial European approval (together with Roche) and subsequently worldwide label-extension work on Neupogen (r-metHu G-CSF, filgrastim), including successful sNDA/AMAA submissions for bone marrow transplantation, paediatric oncology, PBMC mobilisation and HIV-related neutropenia.Key achievements:Established initial clinical development group in UKPromoted to European medical Director and responsible for appointment of national medical staff in EUAuthored Expert Reports for AMAA & Australian submissionsLead presentations at FDA BRMAC/ODAC, EMEA/CHMP and TGALead negotiations with national HTA/re-imbursement agencies including Commision de Transparence (France), Sickfunds (Netherlands), PBAC (Australia)Responsible for medical/marketing activities in EU and Australasia in collaboration with commercial colleagues on secondment for one yearResponsible for training sales representatives

Thousand Oaks, Ca, Us

Mb.Bs, London

Fmgems, Medicine

Master Of Arts (Ma), Physiological Sciences

Bachelor Of Medicine, Bachelor Of Surgery (Mbbs), Medicine

Distinction In Mb. Bs

Master Of Arts (Ma), Medicine

Education record